Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses.

Authors

Elia Segui, Jorge Gomez Tejeda Zañudo, Noah Graham, Patrick T Kurnia, Andrea N Perry, Nabihah Tayob, Heather A Parsons, Raechel Davis, Molly K DiLullo, Jennifer A Ligibel, Filipa Lynce, Jing Ni, Sara M Tolaney, Eric P Winer, Adrienne G Waks, Jean Zhao, Rinath M Jeselsohn, Nancy U Lin, José P Leone

Published in

Cancer research communications. Oct 19, 2026. Epub Oct 19, 2026.

Abstract

HER2+ breast cancer brain metastases (BCBM) frequently harbor PI3K/AKT/mTOR alterations. Preclinical HER2+ BCBM models demonstrated durable tumor regression with dual PI3K and mTOR inhibition. Our phase II trial evaluated paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor, combined with trastuzumab.
Eligible patients had active/progressive HER2+ BCBM and could have received prior therapies; leptomeningeal disease was excluded. The trial included a safety run-in to determine the recommended phase II dose (RP2D), followed by expansion cohorts. The primary endpoint was confirmed central nervous system (CNS) objective response rate (ORR) per Response Assessment in Neuro-Oncology Brain Metastases criteria at the RP2D. Paired plasma and cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) was analyzed using ultra-low-pass whole-genome sequencing and whole-exome sequencing.
Seventeen patients were treated (median age 44 years; median 5 prior therapy lines). Paxalisib 30 mg daily plus trastuzumab was established as the RP2D. Among 12 patients treated at the RP2D, no confirmed CNS responses occurred (CNS ORR, 0%; 95% CI, 0.0-26.5%), and the study closed for futility. Median overall survival was 16.5 months. Treatment was feasible, with a safety profile consistent with PI3K/mTOR inhibition. Exploratory ctDNA analyses showed higher tumor fraction in CSF than plasma, with longitudinal changes in CSF tumor fraction paralleling CNS tumor burden.
Paxalisib combined with trastuzumab was feasible but did not meet the primary endpoint of CNS ORR in heavily pretreated HER2+ BCBM. Exploratory findings suggest that CSF-derived ctDNA may better capture tumor genomics and treatment response than plasma ctDNA in HER2+ BCBM.  .

PMID:
42895898
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.